Gene therapy for hemophilia B: AAV-mediated transfer of the gene for coagulation factor IX to human muscle

Advances in Experimental Medicine and Biology

Volumn 489, Issue , 2001, Pages 45-57

  Larson, P J ^a   High, K A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 9; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADENO ASSOCIATED VIRUS; BLEEDING DISORDER; CONFERENCE PAPER; DOG; DOSE RESPONSE; GENE THERAPY; GENE TRANSFER; HEMOPHILIA B; HUMAN; MUSCLE BIOPSY; PRIORITY JOURNAL; VASTUS LATERALIS MUSCLE;

ADENO-ASSOCIATED VIRUS; CANIS FAMILIARIS;

EID: 0035042012     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-1277-6_4     Document Type: Conference Paper

References (27)

1. Central nervous system bleeding in hemophiliacs
2. Head trauma in hemophilia: A prospective study
3. Hemophilia presenting with intracranial hemorrhage. An approach to the infant with intracranial bleeding and coagulopathy
4. Haemophilia prophylaxis in young patients - A long-term follow-up
5. Annotation. Can haemophilic arthropathy be prevented?
6. Symptomatic parvovirus B19 infection and heat-treated factor IX concentrate
7. Transmission of human parvovirus B19 by plasma derived factor VIII concentrates
8. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100°C heat after lyophilization
9. Molecular cloning and disease association of hepatitis G virus: A transfusion-transmissible agent
10. Presence of a newly described human DNA virus (TTV) in patients with liver disease
11. Association Bulletin 94-4-Hepatitis G virus: Status report and assessment of clinical relevance
12. Canine hemophilia B resulting from a point mutation with unusual consequences
13. The canine factor VIII cDNA and 5′ flanking sequence
14. Targeted disruption of the mouse factor VIII gene: A model for hemophilia A
15. A coagulation factor IX-deficient mouse model for human hemophilia B
16. Production of recombinant adeno-associated viral vectors in N. e. a. Dracopoli
17. Long-term expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
18. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein
19. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector
20. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A
21. A multicenter study of recombinant factor VIII (recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
22. Incidence of inhibitors in patients with severe and moderate hemophilia A treated with factor VIII concentrates
23. Haemophiliacs with factor VIII inhibitors in Finland: Prevalence, incidence and outcome
24. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
25. The incidence of factor VIII inhibitors in patients with severe hemophilia A
26. An estimated frequency of endogenous insertional mutations in humans